Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC

Experts consider how they might approach third-line treatment selection for patients with EGFR exon 20-mutated mNSCLC who experience disease progression on amivantamab or other second-line therapies.

EP: 1.An Introduction to Biomarker Testing in Non-Small Cell Lung Cancer

EP: 2.Analyzing the Relationship Between Biomarkers, Testing Rates, and Clinical Characteristics in Non-Small Cell Lung Cancer

EP: 3.Available Biomarker Testing Modalities for Patients with mNSCLC

EP: 4.Clinical Experience with Coordinating Biomarker Testing for Patients with mNSCLC

EP: 5.Patient Case 1: A 71-year-old Woman with Newly Diagnosed mNSCLC

EP: 6.A Molecular Pathologist’s Insight into Institutional Best Practices for NSCLC Biomarker Testing

EP: 7.Challenges of Using Biomarker Testing in mNSCLC

EP: 8.An Introduction to Three Real-World Analyses of Biomarker Testing Patterns in mNSCLC

EP: 9.Overcoming Disparities in Biomarker Testing Use for mNSCLC

EP: 10.Patient Case 2: mNSCLC with an EGFR Exon 20 Insertion

EP: 11.Managing Disease Progression in Patients with EGFR-mutated mNSCLC

EP: 12.CHRYSALIS: Study Design and Key Results for Amivantamab in mNSCLC

EP: 13.Safety and Efficacy Data for Mobocertinib in Patients with mNSCLC

EP: 14.Data-Informed Insights on Second-line Treatment Selection for EGFR Exon 20-mutated mNSCLC

EP: 15.Patient Case 2: Second-line Treatment Selection and Adverse Event Management

Now Viewing

EP: 16.Insights into Third-Line Treatment Selection for Patients with EGFR Exon 20-mutated mNSCLC

EP: 17.Key Takeaways Regarding Biomarker Testing for mNSCLC

Recent Videos